<DOC>
	<DOC>NCT00436553</DOC>
	<brief_summary>This study evaluated the effect of combination therapy with verteporfin photodynamic therapy and ranibizumab on visual acuity and anatomic outcomes compared to ranibizumab monotherapy and the durability of response observed in patients with choroidal neovascularization secondary to age-related macular degeneration.</brief_summary>
	<brief_title>Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization, Pathologic</mesh_term>
	<mesh_term>Verteporfin</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Subjects of either gender age 50 years or older Subfoveal choroidal neovascularization (CNV) due to agerelated macular degeneration (AMD) Choroidal neovascularization due to causes other than AMD Prior treatment for neovascular AMD in the study eye Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Age-related macular degeneration; AMD</keyword>
	<keyword>choroidal neovascularization</keyword>
	<keyword>verteporfin</keyword>
	<keyword>ranibizumab</keyword>
</DOC>